Tags

Type your tag names separated by a space and hit enter

An orally administered magnoloside A ameliorates functional dyspepsia by modulating brain-gut peptides and gut microbiota.
Life Sci. 2019 Sep 15; 233:116749.LS

Abstract

AIMS

Functional dyspepsia (FD) is very common worldwide with a high prevalence of 10%-30%, and it becomes a heavy burden to patients because of its hard to be cured. In our previous study, phenylethanoid glycosides were found to exist in Houpo, a traditional Chinese medicine commonly used for the treatment of abdominal distention, pain and dyspepsia. In the present study, the effect of magnoloside A (MA), a main phenylethanoid glycoside in Houpo, on FD was firstly evaluated and its potential mechanism was concluded.

MATERIALS AND METHODS

MA was orally administered consequently for 3 weeks, and its effect on a FD rat model established through transient neonatal gastric irritation and mature alternate-day fasting was tested. Levels of brain-gut peptides and inflammatory factors in blood or tissues were determined by ELISA methods. Meanwhile, the gut microbiota was analyzed by 16S rRNA gene sequencing and short chain fat acids were determined by GC/MS.

KEY FINDINGS

MA exhibited anti-FD activities by fastening the delayed gut emptying rate of FD rat and increasing the levels of gastrin, motilin, and calcitonin gene related protein; and decreasing the levels of 5-hydroxytryptamine, nitric oxide synthase, and vasoactive intestinal peptide. On the other hand, MA can modulate the composition of gut microbiota, resulting in the variation of the short chain fat acids.

SIGNIFICANCE

MA ameliorated FD rats by modulating of the secretion of related brain-gut peptides and altering the composition of intestinal microbiota.

Authors+Show Affiliations

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.State Key Laboratory of Dao-di Herbs Breeding Base, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: byang@icmm.ac.cn.State Key Laboratory of Dao-di Herbs Breeding Base, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31412264

Citation

Xue, Zhenzhen, et al. "An Orally Administered Magnoloside a Ameliorates Functional Dyspepsia By Modulating Brain-gut Peptides and Gut Microbiota." Life Sciences, vol. 233, 2019, p. 116749.
Xue Z, Wu C, Wei J, et al. An orally administered magnoloside A ameliorates functional dyspepsia by modulating brain-gut peptides and gut microbiota. Life Sci. 2019;233:116749.
Xue, Z., Wu, C., Wei, J., Xian, M., Wang, T., Yang, B., & Chen, M. (2019). An orally administered magnoloside A ameliorates functional dyspepsia by modulating brain-gut peptides and gut microbiota. Life Sciences, 233, 116749. https://doi.org/10.1016/j.lfs.2019.116749
Xue Z, et al. An Orally Administered Magnoloside a Ameliorates Functional Dyspepsia By Modulating Brain-gut Peptides and Gut Microbiota. Life Sci. 2019 Sep 15;233:116749. PubMed PMID: 31412264.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An orally administered magnoloside A ameliorates functional dyspepsia by modulating brain-gut peptides and gut microbiota. AU - Xue,Zhenzhen, AU - Wu,Changxun, AU - Wei,Junying, AU - Xian,Minghua, AU - Wang,Tingting, AU - Yang,Bin, AU - Chen,Min, Y1 - 2019/08/11/ PY - 2019/05/29/received PY - 2019/08/02/revised PY - 2019/08/10/accepted PY - 2019/8/15/pubmed PY - 2019/10/29/medline PY - 2019/8/15/entrez KW - Brain-gut peptides KW - Functional dyspepsia KW - Gut microbiota KW - Houpo KW - Magnoloside A KW - Short chain fat acids SP - 116749 EP - 116749 JF - Life sciences JO - Life Sci. VL - 233 N2 - AIMS: Functional dyspepsia (FD) is very common worldwide with a high prevalence of 10%-30%, and it becomes a heavy burden to patients because of its hard to be cured. In our previous study, phenylethanoid glycosides were found to exist in Houpo, a traditional Chinese medicine commonly used for the treatment of abdominal distention, pain and dyspepsia. In the present study, the effect of magnoloside A (MA), a main phenylethanoid glycoside in Houpo, on FD was firstly evaluated and its potential mechanism was concluded. MATERIALS AND METHODS: MA was orally administered consequently for 3 weeks, and its effect on a FD rat model established through transient neonatal gastric irritation and mature alternate-day fasting was tested. Levels of brain-gut peptides and inflammatory factors in blood or tissues were determined by ELISA methods. Meanwhile, the gut microbiota was analyzed by 16S rRNA gene sequencing and short chain fat acids were determined by GC/MS. KEY FINDINGS: MA exhibited anti-FD activities by fastening the delayed gut emptying rate of FD rat and increasing the levels of gastrin, motilin, and calcitonin gene related protein; and decreasing the levels of 5-hydroxytryptamine, nitric oxide synthase, and vasoactive intestinal peptide. On the other hand, MA can modulate the composition of gut microbiota, resulting in the variation of the short chain fat acids. SIGNIFICANCE: MA ameliorated FD rats by modulating of the secretion of related brain-gut peptides and altering the composition of intestinal microbiota. SN - 1879-0631 UR - https://www.unboundmedicine.com/medline/citation/31412264/An_orally_administered_magnoloside_A_ameliorates_functional_dyspepsia_by_modulating_brain_gut_peptides_and_gut_microbiota_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(19)30676-9 DB - PRIME DP - Unbound Medicine ER -